New procedure aims to zap nerves to fix slow heartbeat
NCT ID NCT07468383
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a procedure called cardioneuroablation for people with a slow heart rate (bradycardia) caused by overactive vagal nerves. Doctors use a catheter to ablate (destroy) specific nerve clusters in the heart. The trial will enroll 188 participants aged 18-65 and measure changes in average heart rate and quality of life. The goal is to see if this can reduce symptoms like dizziness and fatigue without needing a pacemaker.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cardioneuroablation (catheter procedure to ablate cardiac nerve clusters)
- What this could lead to
- If successful, this procedure could offer a non-drug, non-pacemaker option to control symptoms of slow heart rate caused by overactive vagal nerve activity.
- What could go wrong
- This is an early-stage study with no phase designation, so results are uncertain. The procedure is invasive and carries risks like bleeding, infection, or heart rhythm issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 188 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age range: 18 - 65 years old 2. Have symptoms related to bradycardia (syncope, dizziness, blackout, palpitations, fatigue, listlessness, inability to concentrate and decreased activity endurance, etc.) 3. Meet one of the following conditions: ①Dynamic electrocardiogram shows an average heart rate of less than 50 beats per minute or there is a heart arrest lasting more than 3 seconds during the day; ②Transient second or third degree atrioventricular conduction block without hemodynamic disorders during the day 4. The atropine test showed that the sinus heart rate increased by ≥ 25%, or the heart rate was ≥ 90 beats per minute, or the atrioventricular conduction block was significantly improved to be no more than first-degree atrioventricular conduction block. Exclusion Criteria: 1. A history of severe trauma caused by bradycardia 2. Regular use of antiarrhythmic drugs within the past 3 months 3. Prior implantation of a cardiac pacemaker 4. Existing implantation of, or indication for implantation of, electronic devices with pacing function, such as cardiac contractility modulators (CCMs), implantable cardioverter-defibrillators (ICDs), or cardiac resynchronization therapy (CRT) devices 5. Bradycardia or atrioventricular block caused by medications or other reversible factors (e.g., hyperkalemia, hypothyroidism) 6. Bradycardia or atrioventricular block associated with obstructive sleep apnea syndrome (OSAS) 7. Coronary revascularization within the past 3 months, or unstable coronary heart disease despite standardized medical treatment or revascularization 8. Stroke or transient ischemic attack (TIA) within the past 3 months 9. A history of open-heart surgery 10. Severe congenital heart disease 11. Complicated with severe ventricular arrhythmia 12. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) ≤ 35% 13. Severe cardiomyopathy, such as hypertrophic obstructive cardiomyopathy (HOCM), dilated cardiomyopathy (DCM), or cardiac amyloidosis 14. Severe aortic or mitral valve stenosis 15. Pregnancy or lactation period 16. Expected survival time of less than 1 year 17. Refusal to sign the informed consent form 18. Other conditions deemed ineligible by the researchers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autonomic nervous system diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University
RECRUITINGBeijing, China, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smarter pacemaker setting sharpen the mind?
- Can two common drugs tame the debilitating symptoms of POTS?
- Tiny nodules in connective tissue may reveal hidden clues about organ health
- Healthy volunteers needed to map the Body's 'Autopilot' system
- Exercise eases menopause symptoms and boosts heart health in new study
- New pacemaker lead aims to improve heart function in bradycardia patients